Charles River Laboratories International (CRL) Net Income towards Common Stockholders (2009 - 2025)

Charles River Laboratories International's Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$276.6 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders fell 28.21% year-over-year to -$276.6 million; the TTM figure through Dec 2025 stood at -$144.3 million (down 1501.75% YoY), while the FY2025 annual figure was -$144.3 million, down 1501.75% from the prior year.
• Net Income towards Common Stockholders was -$276.6 million for Q4 2025 at Charles River Laboratories International, down from $54.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $189.1 million in Q4 2022 to a low of -$276.6 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged $61.6 million across 5 years, with a median of $90.0 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders surged 48.94% in 2022, then slumped 215.3% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $139.8 million in 2021, then surged by 35.24% to $189.1 million in 2022, then fell by 1.07% to $187.1 million in 2023, then plunged by 215.3% to -$215.7 million in 2024, then slipped by 28.21% to -$276.6 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$276.6 million (Q4 2025), $54.4 million (Q3 2025), and $52.3 million (Q2 2025), per Business Quant data.